Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 61 AL 75

Advances in prodrug design for Alzheimer's disease: the state of the art

Travers-Lesage V, Mignani SM, Dallemagne P, Rochais C.

Expert Opin Drug Discov. 2022 Apr;17(4):325-341. doi: 10.1080/17460441.2022.2031972. Epub 2022 Feb 23.

Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential

Gao L, Zhang Y, Sterling K, Song W.

Transl Neurodegener. 2022 Jan 28;11(1):4. doi: 10.1186/s40035-022-00279-0.

Regulatory decisions diverge over aducanumab for Alzheimer's disease

Lythgoe MP, Jenei K, Prasad V.

BMJ. 2022 Jan 28;376:e069780. doi: 10.1136/bmj-2021-069780.

Alzheimer's disease therapy based on acetylcholinesterase inhibitor/blocker effects on voltage-gated potassium channels

Li XT.

Metab Brain Dis. 2022 Mar;37(3):581-587. doi: 10.1007/s11011-022-00921-w. Epub 2022 Jan 31.

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial

Gonzales MM, Garbarino VR, Marques Zilli E, Petersen RC, Kirkland JL, Tchkonia T, Musi N, Seshadri S, Craft S, Orr ME.

J Prev Alzheimers Dis. 2022;9(1):22-29. doi: 10.14283/jpad.2021.62.

Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer's disease: a systematic review and meta-analysis

Wang H, Zong Y, Han Y, Zhao J, Liu H, Liu Y.

Expert Opin Drug Saf. 2022 Mar;21(3):407-415. doi: 10.1080/14740338.2022.2027905. Epub 2022 Jan 31.

Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review

Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F.

JAMA Neurol. 2022 Mar 1;79(3):291-304. doi: 10.1001/jamaneurol.2021.5205.

Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs

Reiman EM, Mattke S, Kordower JH, Khachaturian ZS, Khachaturian AS.

Alzheimers Dement. 2022 Jan;18(1):7-9. doi: 10.1002/alz.12533. Epub 2022 Feb 1.

The calcium-free form of atorvastatin inhibits amyloid-β(1-42) aggregation in vitro

Nedaei H, Rezaei-Ghaleh N, Giller K, Becker S, Karami L, Moosavi-Movahedi AA, Griesinger C, Saboury AA.

J Biol Chem. 2022 Mar;298(3):101662. doi: 10.1016/j.jbc.2022.101662. Epub 2022 Jan 30.

Human iPSC-Derived Neural Models for Studying Alzheimer's Disease: from Neural Stem Cells to Cerebral Organoids

Barak M, Fedorova V, Pospisilova V, Raska J, Vochyanova S, Sedmik J, Hribkova H, Klimova H, Vanova T, Bohaciakova D.

Stem Cell Rev Rep. 2022 Feb;18(2):792-820. doi: 10.1007/s12015-021-10254-3. Epub 2022 Feb 2.

Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease

Taliyan R, Kakoty V, Sarathlal KC, Kharavtekar SS, Karennanavar CR, Choudhary YK, Singhvi G, Riadi Y, Dubey SK, Kesharwani P.

J Control Release. 2022 Mar;343:528-550. doi: 10.1016/j.jconrel.2022.01.044. Epub 2022 Jan 31.

Physiology and pharmacology of amyloid precursor protein

Cho Y, Bae HG, Okun E, Arumugam TV, Jo DG.

Pharmacol Ther. 2022 Jul;235:108122. doi: 10.1016/j.pharmthera.2022.108122. Epub 2022 Feb 1.

A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis

Shukla M, Wongchitrat P, Govitrapong P.

Neurochem Res. 2022 May;47(5):1166-1182. doi: 10.1007/s11064-022-03530-2. Epub 2022 Feb 5.

What have we learnt from past failures in Alzheimer's disease drug discovery?

Cacabelos R.

Expert Opin Drug Discov. 2022 Apr;17(4):309-323. doi: 10.1080/17460441.2022.2033724. Epub 2022 Feb 6.

Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey

DiStefano MJ, Alexander GC, Polsky D, Anderson GF.

J Am Geriatr Soc. 2022 Jun;70(6):1685-1694. doi: 10.1111/jgs.17692. Epub 2022 Feb 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias